Overall, a better characterization of the SYK phosphorylation signaling pathways in different tissue types is crucial because pharmacological SYK inhibitors are now used in the clinic to treat immune thrombocytopenia, autoimmune hemolytic anemia and IgA nephropathy [76]. Here, SYK is linked to IgA glomerulonephritis.